Loading...

Applied DNA Sciences

DB:UDJN
Snowflake Description

Limited growth with imperfect balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
UDJN
DB
$22M
Market Cap
  1. Home
  2. DE
  3. Tech
Company description

Applied DNA Sciences, Inc. develops and markets plat based or other DNA technology solution in the United States, Europe, and Asia. The last earnings update was 77 days ago. More info.


Add to Portfolio Compare Print
  • Applied DNA Sciences has significant price volatility in the past 3 months.
UDJN Share Price and Events
7 Day Returns
1.4%
DB:UDJN
1.6%
DE Electronic
0.8%
DE Market
1 Year Returns
-57.3%
DB:UDJN
2.7%
DE Electronic
-4.5%
DE Market
UDJN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Applied DNA Sciences (UDJN) 1.4% 6.4% 2.2% -57.3% -80.6% -
DE Electronic 1.6% 10.5% 19.9% 2.7% 97.7% 106%
DE Market 0.8% 6.9% 8.1% -4.5% 10.4% 13.9%
1 Year Return vs Industry and Market
  • UDJN underperformed the Electronic industry which returned 2.7% over the past year.
  • UDJN underperformed the Market in Germany which returned -4.5% over the past year.
Price Volatility
UDJN
Industry
5yr Volatility vs Market
Related Companies

UDJN Value

 Is Applied DNA Sciences undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Applied DNA Sciences. This is due to cash flow or dividend data being unavailable. The share price is €0.517.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Applied DNA Sciences's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Applied DNA Sciences's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:UDJN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.39
NasdaqCM:APDN Share Price ** NasdaqCM (2019-04-25) in USD $0.59
Germany Electronic Industry PE Ratio Median Figure of 13 Publicly-Listed Electronic Companies 23.82x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.1x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Applied DNA Sciences.

DB:UDJN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:APDN Share Price ÷ EPS (both in USD)

= 0.59 ÷ -0.39

-1.51x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Applied DNA Sciences is loss making, we can't compare its value to the DE Electronic industry average.
  • Applied DNA Sciences is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Applied DNA Sciences's expected growth come at a high price?
Raw Data
DB:UDJN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.51x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
34.7%per year
Germany Electronic Industry PEG Ratio Median Figure of 12 Publicly-Listed Electronic Companies 2.18x
Germany Market PEG Ratio Median Figure of 268 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Applied DNA Sciences, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Applied DNA Sciences's assets?
Raw Data
DB:UDJN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.02
NasdaqCM:APDN Share Price * NasdaqCM (2019-04-25) in USD $0.59
Germany Electronic Industry PB Ratio Median Figure of 19 Publicly-Listed Electronic Companies 2.57x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:UDJN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:APDN Share Price ÷ Book Value per Share (both in USD)

= 0.59 ÷ 0.02

27.32x

* Primary Listing of Applied DNA Sciences.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Applied DNA Sciences is overvalued based on assets compared to the DE Electronic industry average.
X
Value checks
We assess Applied DNA Sciences's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Electronic industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Electronic industry average (and greater than 0)? (1 check)
  5. Applied DNA Sciences has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

UDJN Future Performance

 How is Applied DNA Sciences expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
34.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Applied DNA Sciences expected to grow at an attractive rate?
  • Unable to compare Applied DNA Sciences's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Applied DNA Sciences's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Applied DNA Sciences's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:UDJN Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:UDJN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 34.7%
DB:UDJN Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 46%
Germany Electronic Industry Earnings Growth Rate Market Cap Weighted Average 12.9%
Germany Electronic Industry Revenue Growth Rate Market Cap Weighted Average 7.9%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:UDJN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:UDJN Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-09-30 13 -6 2
2019-09-30 11 -7 2
DB:UDJN Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 4 -6 -12
2018-09-30 4 -7 -12
2018-06-30 4 -5 -11
2018-03-31 5 -6 -11
2017-12-31 4 -8 -12
2017-09-30 5 -7 -13
2017-06-30 5 -9 -12
2017-03-31 4 -9 -13
2016-12-31 4 -9 -13
2016-09-30 4 -10 -12
2016-06-30 7 -9 -10
2016-03-31 8 -8 -9

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Applied DNA Sciences is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Applied DNA Sciences's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:UDJN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Applied DNA Sciences Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:UDJN Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-09-30 -0.15 -0.10 -0.20 2.00
2019-09-30 -0.22 -0.21 -0.22 2.00
DB:UDJN Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.39
2018-09-30 -0.40
2018-06-30 -0.38
2018-03-31 -0.39
2017-12-31 -0.45
2017-09-30 -0.49
2017-06-30 -0.49
2017-03-31 -0.53
2016-12-31 -0.54
2016-09-30 -0.51
2016-06-30 -0.44
2016-03-31 -0.38

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Applied DNA Sciences will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Applied DNA Sciences's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Applied DNA Sciences has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

UDJN Past Performance

  How has Applied DNA Sciences performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Applied DNA Sciences's growth in the last year to its industry (Electronic).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Applied DNA Sciences does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Applied DNA Sciences's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Applied DNA Sciences's 1-year growth to the DE Electronic industry average as it is not currently profitable.
Earnings and Revenue History
Applied DNA Sciences's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Applied DNA Sciences Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:UDJN Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 4.14 -11.74 11.53 2.72
2018-09-30 3.90 -11.69 11.04 2.75
2018-06-30 3.85 -11.07 10.26 2.56
2018-03-31 4.63 -10.80 10.78 2.54
2017-12-31 4.50 -12.08 12.02 2.50
2017-09-30 4.75 -12.86 13.32 2.28
2017-06-30 5.24 -12.42 13.16 2.60
2017-03-31 4.10 -13.17 12.32 3.11
2016-12-31 3.77 -13.21 11.54 3.55
2016-09-30 4.19 -12.18 10.81 3.70
2016-06-30 6.53 -10.26 11.09 3.85
2016-03-31 8.15 -8.56 11.28 3.67
2015-12-31 9.09 -6.98 11.72 2.97
2015-09-30 9.01 -11.88 13.23 2.58
2015-06-30 5.67 -13.49 13.48 1.80
2015-03-31 4.25 -13.74 13.68 1.13
2014-12-31 3.37 -14.60 14.08 1.12
2014-09-30 2.72 -13.07 13.25 1.30
2014-06-30 2.80 -14.68 12.78 1.27
2014-03-31 2.61 -14.90 13.07 1.19
2013-12-31 2.32 -15.27 12.52 1.00
2013-09-30 2.04 -17.69 11.20 0.69
2013-06-30 1.60 -15.74 10.40 0.67
2013-03-31 1.48 -15.03 8.91 0.58
2012-12-31 1.66 -13.45 7.98 0.50
2012-09-30 1.85 -7.15 7.62 0.43
2012-06-30 1.84 -9.80 9.59 0.38

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Applied DNA Sciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Applied DNA Sciences has efficiently used its assets last year compared to the DE Electronic industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Applied DNA Sciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Applied DNA Sciences's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Electronic industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Applied DNA Sciences has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

UDJN Health

 How is Applied DNA Sciences's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Applied DNA Sciences's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Applied DNA Sciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Applied DNA Sciences's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Applied DNA Sciences's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Applied DNA Sciences Company Filings, last reported 3 months ago.

DB:UDJN Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 0.77 2.14 3.14
2018-09-30 0.75 1.59 1.66
2018-06-30 3.06 0.00 2.51
2018-03-31 5.71 0.00 3.71
2017-12-31 8.14 0.00 4.76
2017-09-30 6.86 0.00 2.96
2017-06-30 8.02 0.00 2.40
2017-03-31 9.29 0.00 4.02
2016-12-31 12.18 0.00 6.70
2016-09-30 10.37 0.00 4.48
2016-06-30 12.19 0.00 7.09
2016-03-31 15.03 0.00 9.79
2015-12-31 18.00 0.00 12.38
2015-09-30 12.57 0.00 7.31
2015-06-30 12.50 0.00 10.73
2015-03-31 1.96 0.00 0.98
2014-12-31 3.30 0.00 2.87
2014-09-30 -1.47 1.80 1.39
2014-06-30 0.31 0.00 2.03
2014-03-31 -0.32 0.00 1.99
2013-12-31 1.88 0.00 4.20
2013-09-30 4.62 0.00 6.36
2013-06-30 2.31 0.00 1.83
2013-03-31 -3.77 0.00 4.41
2012-12-31 -6.70 0.00 0.98
2012-09-30 0.76 0.00 0.72
2012-06-30 1.32 0.25 1.26
  • Applied DNA Sciences's level of debt (279.5%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 279.5% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Applied DNA Sciences has less than a year of cash runway based on current free cash flow.
  • Applied DNA Sciences has less than a year of cash runway if free cash flow continues to reduce at historical rates of -14.9% each year.
X
Financial health checks
We assess Applied DNA Sciences's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Applied DNA Sciences has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

UDJN Dividends

 What is Applied DNA Sciences's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Applied DNA Sciences dividends.
If you bought €2,000 of Applied DNA Sciences shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Applied DNA Sciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Applied DNA Sciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:UDJN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Germany Electronic Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:UDJN Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2020-09-30
2019-09-30

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Applied DNA Sciences has not reported any payouts.
  • Unable to verify if Applied DNA Sciences's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Applied DNA Sciences's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Applied DNA Sciences has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Applied DNA Sciences's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Applied DNA Sciences afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Applied DNA Sciences has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

UDJN Management

 What is the CEO of Applied DNA Sciences's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
James Hayward
COMPENSATION $433,000
AGE 64
TENURE AS CEO 13.1 years
CEO Bio

Dr. James A. Hayward, Ph.D.,Sc.D. has been Chief Executive Officer and Chairman of Applied DNA Sciences Inc. (Formerly Known as Prohealth Medical Tech, Inc) since March 17, 2006 and since June 12, 2007 respectively. Dr. Hayward has been the President of Applied DNA Sciences Inc., since June 12, 2007. He is a General Partner at Double D Venture Fund. He has over 15 years of experience in the consumer product, biotech and pharmaceutical industries. He founded Collaborative Laboratories Inc. (CLI) in 1990 and served as its President. In 1990, Dr. Hayward founded The Collaborative Group. For 14 years, he served as Chairman, President and Chief Executive Officer of Collaborative, The Collaborative BioAlliance, and Collaborative Labs. Dr. Hayward served as Principal Financial Officer and Principal Accounting Officer of Applied DNA Sciences Inc., since October 17, 2005 and served as its Acting Chief Executive Officer from October 5, 2005 to March 17, 2006. He served as Vice President of Personal Care & Life Sciences for BASF Catalysts LLC (also known as Engelhard Corp.), since August 2004. From 1990 to July 2004, he served as Chairman, President and Chief Executive of Collaborative Group Ltd. In 1983, Dr. Hayward was one of the founding Principals and Research Director of Biocompatibles Ltd. He has been a Director of Applied DNA Sciences Inc., since 2006. From 1984 to 1989, he was responsible for product development at Esteé Lauder Companies, where he served as Director of Research Worldwide. Since June 2004, Dr. Hayward has been the Chairman of Evotope Biosciences Inc. Since 2001, he has been a Director of Q-RNA, Inc. He serves on the boards of the Council on Biotechnology and the Research Foundation of the State of New York (Research Foundation Of State University Of New York, The). He serves as a Director of Softheon, Inc,Regents Council and NeoMatrix Formulations, Inc. He served as Director of Long Island Life Sciences Initiative (LILSI), Long Island Association Inc., Stony Brook Foundation, and the New York Biotechnology Association Inc. Dr. Hayward has more than 50 patents and original publications to his credit regarding the applications of liposomes. Dr. Hayward has been twice named Entrepreneur of the Year; in 2002 by Inc. Magazine and in 2009 by the Long Island Technology Hall of Fame. In January 2014, Dr. Hayward was given the David Award by Networking Magazine as one of eight of Long Island's most accomplished individuals. He received his Doctorate in Molecular Biology and Biophysics from SUNY at Stony Brook. Dr. Hayward received his Bachelors degree in Biology and Chemistry from the State University of New York at Oneonta in 1976 and his Ph.D. in Molecular Biology from the State University of New York at Stony Brook in 1983.

CEO Compensation
  • James's compensation has been consistent with company performance over the past year.
  • James's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Applied DNA Sciences management team in years:

8.8
Average Tenure
60
Average Age
  • The average tenure for the Applied DNA Sciences management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

James Hayward

TITLE
President
COMPENSATION
$433K
AGE
64
TENURE
13.1 yrs

Beth Jantzen

TITLE
Chief Financial Officer
COMPENSATION
$288K
AGE
42
TENURE
4.2 yrs

Judy Murrah

TITLE
Chief Information Officer & Secretary
COMPENSATION
$339K
AGE
60
TENURE
5.8 yrs

Clay Shorrock

TITLE
General Counsel

Tony Benson

TITLE
Managing Director of EMEA
TENURE
8.2 yrs

Janice Meraglia

TITLE
Vice President

Stephen Hughes

TITLE
Director of DNA Programs

Joseph Magno

TITLE
Sales Consultant
TENURE
9.5 yrs

Warren Pearlson

TITLE
Sales Consultant
TENURE
9.5 yrs
Board of Directors Tenure

Average tenure and age of the Applied DNA Sciences board of directors in years:

6
Average Tenure
64
Average Age
  • The tenure for the Applied DNA Sciences board of directors is about average.
Board of Directors

James Hayward

TITLE
President
COMPENSATION
$433K
AGE
64
TENURE
11.8 yrs

Yacov Shamash

TITLE
Independent Director
COMPENSATION
$95K
AGE
68
TENURE
13.1 yrs

John Bitzer

TITLE
Independent Director
COMPENSATION
$81K
AGE
57
TENURE
7.7 yrs

Bob Catell

TITLE
Chairman of Strategic Advisory Board & Director
COMPENSATION
$88K
AGE
81
TENURE
3.2 yrs

Sanford Simon

TITLE
Independent Director
COMPENSATION
$80K
AGE
76
TENURE
13.1 yrs

Charles Ryan

TITLE
Independent Director
COMPENSATION
$81K
AGE
54
TENURE
7.7 yrs

Joe Ceccoli

TITLE
Independent Director
COMPENSATION
$88K
AGE
56
TENURE
4.3 yrs

Gunther Faber

TITLE
Member of Strategic Advisory Board
TENURE
3.2 yrs

Mehmood Khan

TITLE
Member of Strategic Advisory Board
AGE
59
TENURE
2.5 yrs

Ray Kelly

TITLE
Member of Strategic Advisory Board
AGE
77
TENURE
2.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
24. Jan 19 Buy William Montgomery Individual 23. Jan 19 24. Jan 19 140,000 €0.42 €57,506
22. Jan 19 Buy William Montgomery Individual 18. Jan 19 22. Jan 19 160,000 €0.39 €62,581
08. Jan 19 Buy William Montgomery Individual 31. Dec 18 07. Jan 19 400,000 €0.41 €155,916
X
Management checks
We assess Applied DNA Sciences's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Applied DNA Sciences has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

UDJN News

Simply Wall St News

UDJN Company Info

Description

Applied DNA Sciences, Inc. develops and markets plat based or other DNA technology solution in the United States, Europe, and Asia. The company’s supply chain security and product authentication solutions include SigNature molecular tags that are ingredients used to fortify brand protection efforts and strengthen supply chain security, as well as mark, track, and convict criminals; SigNature T molecular tags, which are tagging and authentication systems for use in brand protection efforts and raw material source compliance programs; and fiberTyping, a test of native cotton fiber DNA. It also provides DNAnet, Smart DNA, and Backtrac that are molecular tags to link evidence and offenders to specific crime scenes; Beacon locked optical markers, which create a protected covert screening tool that can be adapted to packaging, security labels, and high–value assets through inks, varnishes, and coatings; and SigNify IF portable DNA readers that provides real-time authentication of molecular tags. In addition, the company offers Applied DNA Sciences Portal, a software platform that enables customers to manage the security of company-marked goods from point of marking to point of authentication or validation to end of life; and DNA Transfer Systems and Cannabis Tracking System, which offer remote Internet access for real-time monitoring. Further, it provides CertainT Supply Chain Platform that provides proof of product claims for materials, items, or products; and Triathlon PCR systems that allow for the large-scale production of specific DNA sequences. Additionally, the company offers contract research services for the nucleic acid-based medical and biologic markets; and various RNA based drug and biologic customers for preclinical studies. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.

Details
Name: Applied DNA Sciences, Inc.
UDJN
Exchange: DB
Founded: 1983
$19,349,176
36,847,857
Website: http://www.adnas.com
Address: Applied DNA Sciences, Inc.
50 Health Sciences Drive,
Stony Brook,
New York, 11790,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM APDN Common Stock Nasdaq Capital Market US USD 19. Nov 2002
DB UDJN Common Stock Deutsche Boerse AG DE EUR 19. Nov 2002
LSE 0HGQ Common Stock London Stock Exchange GB USD 19. Nov 2002
Number of employees
Current staff
Staff numbers
59
Applied DNA Sciences employees.
Industry
Electronic Equipment and Instruments
Tech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 20:33
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2019/03/29
Last earnings filing: 2019/02/07
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/09/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.